Close Menu

Yourgene

Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.

The company said its higher revenues were due in part to international performance including continued penetration of Middle Eastern and Asian markets.

Under the terms of the agreement, Yourgene will offer its NIPT products on Thermo's NGS instruments in Southeast Asia and pay off its debts to Thermo.

The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.

A brief recap of Genetics/Genomics news the week of Oct 5, 2018: OncoDNA, Interpace Diagnostics, B. Braun Melsungen & CeGat, and Premaitha

The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.

The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.

By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.

Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.

Pages

According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.

In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.